UAB Profarma – Product Pipeline Review

Global Markets Direct’s, ‘UAB Profarma – Product Pipeline Review – 2016’, provides an overview of the UAB Profarma’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by UAB Profarma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of UAB Profarma

The report provides overview of UAB Profarma including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses UAB Profarma’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features UAB Profarma’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate UAB Profarma’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for UAB Profarma

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding UAB Profarma’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

UAB Profarma Snapshot 5

UAB Profarma Overview 5

Key Information 5

Key Facts 5

UAB Profarma - Research and Development Overview 6

Key Therapeutic Areas 6

UAB Profarma - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

UAB Profarma - Pipeline Products Glance 10

UAB Profarma - Early Stage Pipeline Products 10

Preclinical Products/Combination Treatment Modalities 10

Discovery Products/Combination Treatment Modalities 11

UAB Profarma - Drug Profiles 12

PF-01 12

Product Description 12

Mechanism of Action 12

R&D Progress 12

PF-04 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

PF-05 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

PF-02 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

PF-03 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

PF-06 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

PF-07 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

PF-08 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

UAB Profarma - Pipeline Analysis 20

UAB Profarma - Pipeline Products by Target 20

UAB Profarma - Pipeline Products by Molecule Type 21

UAB Profarma - Pipeline Products by Mechanism of Action 22

UAB Profarma - Dormant Projects 23

UAB Profarma - Locations And Subsidiaries 24

Head Office 24

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 25

Disclaimer 26

List of Tables

List of Tables

UAB Profarma, Key Information 5

UAB Profarma, Key Facts 5

UAB Profarma – Pipeline by Indication, 2016 7

UAB Profarma – Pipeline by Stage of Development, 2016 8

UAB Profarma – Monotherapy Products in Pipeline, 2016 9

UAB Profarma – Preclinical, 2016 10

UAB Profarma – Discovery, 2016 11

UAB Profarma – Pipeline by Target, 2016 20

UAB Profarma – Pipeline by Molecule Type, 2016 21

UAB Profarma – Pipeline Products by Mechanism of Action, 2016 22

UAB Profarma – Dormant Developmental Projects,2016 23

List of Figures

List of Figures

UAB Profarma – Pipeline by Indication, 2016 7

UAB Profarma – Pipeline by Stage of Development, 2016 8

UAB Profarma – Monotherapy Products in Pipeline, 2016 9

UAB Profarma – Pipeline by Target, 2016 20

UAB Profarma – Pipeline by Molecule Type, 2016 21

UAB Profarma – Pipeline Products by Mechanism of Action, 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports